BioSpace News Archive

HTG Molecular Diagnostics, Inc., a life science company whose mission is to advance precision medicine, announced it has received the first commercial orders for its planned HTG Transcriptome Panel and has signed agreements with its first two Early Adopter Program collaborators in Europe.

Imbria Pharmaceuticals today announced that the first 10 (ten) patients were dosed in the IMPROVE-DiCE Phase 2a, open-label study of IMB-1018972 (IMB-101) in patients with Type 2 diabetes at risk of diabetic cardiomyopathy.

Applied Biological Laboratories announced that its study published online in Immunology, Inflammation and Disease was able to determine the mechanism behind respiratory inflammation and treat it effectively with Biovanta™.

Avisa Diagnostics Inc., a clinical-stage medical device company developing an ultra-rapid, point-of-care biomarker breath test for the detection and monitoring of bacterial load in post-COVID-19 long haulers and for ventilator-associated pneumonia, is pleased to announce that G. Michael Landis has joined Avisa as Chief Financial Officer, effective immediately.

Anavex Life Sciences Corp. announced that it has entered into a definitive purchase agreement with Deep Track Capital for the issuance and sale of an aggregate of 2,380,953 shares of its common stock at a purchase price of $21.00 per share of common stock, a registered direct offering.

BD, a leading global medical technology company, issued its 2020 Sustainability Report, highlighting significant achievements in environmental, social and governance factors that supported the company’s 2020 Sustainability Goals – a five year strategy that concluded in 2020.

Cytovale, a medical diagnostics company focused on providing a more rapid and insightful way to diagnose fast-moving and immune mediated diseases, announced the publication of a study in the peer-reviewed journal Critical Care Explorations evaluating its IntelliSep test as a tool in the rapid diagnosis of sepsis in the hospital emergency department.

BioBam announced last week the release of OmicsBox 2.0. This new version of BioBam’s bioinformatics solution offers a user-friendly data analysis platform that allows researchers to easily gain biological insights from next-generation sequencing data.

Dicerna Pharmaceuticals, Inc. announced it has initiated patient dosing in the Company’s Phase 2 ESTRELLA trial of belcesiran, an investigational GalXC™ RNAi therapeutic candidate for the treatment of alpha-1 antitrypsin (AAT) deficiency-associated liver disease (AATLD).

Small Pharma Inc. is pleased to announce that it has retained LifeSci Advisors, LLC to provide investor relations services.